Innovation
In traditional drug and device development, early-stage investments (from research to preclinical) yield minimal return, creating a funding gap known as the “valley of death.” Although return on investment (ROI) remains low initially, completing Phase I clinical trials significantly increases a project’s market potential (by 125%), justifying stronger UZH ownership or licensing terms. The largest value increase and ROI occurs after Phase II (clinical proof-of-concept), which is where investors typically become interested.
The vision of ZH3D is to support and advance academic innovation in the field of drug and device development by providing GxP expertise and quality assurance. The benefits of local, GxP-compliant academic innovation is important. Locally conducted, applied academic projects lead to higher success rates, greater chances of locally taxed company formation, and stronger ownership positions for founders and universities. They also promote the education and availability of highly qualified personnel in GxP and regulatory fields, which in turn supports new company formation, enhances the attractiveness of the region to industry, and strengthens the innovation ecosystem.
In order to achieve this goal, ZH3D will work closely with other agencies supporting innovation such as:
Translational Medicine Accelerator